Review of Techniques for Evaluating Liver Fibrosis in HCV Patients
Author Information
Author(s): Ahmad Waqar, Ijaz Bushra, Gull Sana, Asad Sultan, Khaliq Saba, Jahan Shah, Sarwar Muhammad T, Kausar Humera, Sumrin Aleena, Shahid Imran, Hassan Sajida
Primary Institution: Applied and Functional Genomics Laboratory, Centre of Excellence in Molecular Biology, University of the Punjab, Lahore, Pakistan
Hypothesis
Non-invasive methods can effectively assess liver fibrosis in HCV patients and may replace liver biopsy in the future.
Conclusion
Non-invasive markers like FibroTest and Fibroscan show promise in predicting liver fibrosis stages, but none are as accurate as liver biopsy.
Supporting Evidence
- FibroTest and Fibroscan have high predictive values for liver fibrosis.
- Non-invasive methods are less risky than liver biopsy.
- Genetic markers may help in differentiating fibrosis stages.
Takeaway
Doctors can use blood tests and imaging instead of a liver biopsy to check for liver damage in patients with hepatitis C.
Methodology
The review analyzed over 200 studies on invasive and non-invasive markers for diagnosing liver fibrosis in HCV patients.
Limitations
No single non-invasive marker can differentiate all stages of fibrosis, and some methods have low predictive values.
Participant Demographics
Patients with chronic hepatitis C, with a focus on various fibrosis stages.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website